1223498-32-5Relevant articles and documents
The lab oddity prevails: Discovery of Pan-CDK inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY1000394) for the treatment of cancer
Luecking, Ulrich,Jautelat, Rolf,Krueger, Martin,Brumby, Thomas,Lienau, Philip,Schaefer, Martina,Briem, Hans,Schulze, Julia,Hillisch, Alexander,Reichel, Andreas,Wengner, Antje Margret,Siemeister, Gerhard
, p. 1067 - 1085 (2013/07/26)
Lead optimization of a high-throughput screening hit led to the rapid identification of aminopyrimidine ZK304709, a multitargeted CDK and VEGF-R inhibitor that displayed a promising preclinical profile. Nevertheless, ZK304709 failed in phaseI studies due